California is denying popular and effective weight loss drugs to poor people — likely to spite President Donald Trump, who has tried to make them cheaper.

LOTTE Holdings, Co., Ltd. (Tokyo, Japan; CEO: Genichi Tamatsuka, hereinafter “LOTTE Holdings”) announces an investment in Alveus Therapeutics, Inc. (hereinafter “Alveus Therapeutics”), a rapidly ...

The companies have identified an initial set of genetic biomarkers to predict drug response and will validate the findings in ...

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular ...

It's 'definitely not a measure of fatness,' and it doesn't accurately define what it means to be overweight. Body mass index isn't always the best predictor of health. In the age of weight-loss drugs, ...

Researchers found that the risk of type 2 diabetes varies among young adults. Those with high fasting glucose who qualified for GLP-1 treatment had a higher risk of type 2 diabetes, suggesting that ...

A research team affiliated with UNIST has made a significant discovery explaining why liver cancers associated with obesity and metabolic disorders tend to be more aggressive and less responsive to ...

With obesity rates hovering around one in three adults, looser pricing could make semaglutide standard of care ...

In addition to their weight loss benefits, GLP-1 RAs also act on neural circuits involved in appetite, impulse control, and ...

A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, ...